All lobbying filings

DLA PIPER LLP (US)

Lobbying for NOVARTIS · Innovative medicines company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 3

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 5

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Taxation/Internal Revenue Code

Tax reform and tax policy.

Trade (domestic/foreign)

Tariffs and biotechnology issues related to Treasury and competition with China.

Health Issues

Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.

Medicare/Medicaid

Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.